S-adenosylmethionine (SAM

Abstract
Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.
Cerebrospinalfluid S-adenosylmethionine in depression and dementia were seen in patients with multiple sclerosis. Although for this control subgroup the increase in CSF SAM compared with the remaining control subgroup was not statistically significant we have documented the two control subgroups separately. Statistically significant lowering of CSF SAM was found in the groups with depression and with Alzheimer's dementia compared with the neurological control group and with the two individual subgroups; the lowest levels occurring in the Alzheimer's group (table 1) . The administration of intravenous SAM 200 mgs daily for two weeks to depressed patients is associated with a significant rise in CSF SAM, a phenomenon which is not seen after two weeks treatment with placebo (table  2) . Higher values for CSF SAM are seen two hours after the last injection (67% increase) than 24 hours after the last injection (19% increase) (table 2). Oral SAM treatment (1200 mgs daily) for four to eight months was associated with a significant increase (62 5%) in CSF SAM in patients with Alzheimer's dementia (table 3) . The post-treatment values were within the neurological control range (tables 1 and 3). Discussion S-adenosylmethionine is a ubiquitous metabolite which, when administered intravenously in normal subjects and patients in single doses varying from 100 to 500 mgs, is rapidly eliminated from the circulation with a half-life of about 90 minutes. '5 We have previously shown that following single oral doses of 400 to 1000 mgs in normal subjects peak plasma levels are achieved between two and six hours and SAM is thereafter rapidly metabolised from the circulation. '6 In this study we have shown that following intravenous or oral administration SAM crosses the blood-brain barrier leading to a rise in CSF SAM (tables 2 and 3). In the placebo controlled study in depressed patients CSF SAM was re-examined either two or 24 hours after the last of 14 daily injections. In keeping with the pharmacokinetics of SAM in blood the greatest rise (67%) in CSF was seen at two hours, but even at 24 hours there was a 19% elevation. No rise was seen with placebo at two or 24 hours. After oral administration of SAM continuously for four to eight months in demented patients CSF SAM rose by nearly two-thirds from baseline levels into the control range.
The therapeutic potential of SAM in some forms of depression, especially endogenous depression, has now been reported in several countries.`-Until recently the trials have utilised parenteral SAM, but longer term oral SAM studies are now showing promising results.'3 '7'8 SAM is remarkably free from side effects, the main problem being the precipitation of hypomania or mania in some patients with bipolar depression (which can occur with any antidepressant), and is further evidence of its efficacy. '8 We have demonstrated in a large series of severely depressed patients that CSF SAM is significantly lower than in two neurological control groups (table 1) . Although in the subgroup of multiple sclerotic patients the CSF SAM is not significantly higher than the other neurological control patients the trend is such that we thought it appropriate to keep the subgroups separate, especially as some patients have been described recently with multiple sclerosis associated with abnormalities of vitamin B12 metabolism.'9 The low level of CSF SAM in some patients with depression suggests that there may be an underlying disturbance in methylation within the nervous system and provides a rational basis for the therapeutic use of SAM, at least in this subgroup. We have recently confirmed other evidence of abnormal methylation in depression in the form of reduced erythrocyte methionine adenosyltransferase (MAT) activity,'6 as was earlier reported by Alarcon et al.20 MAT is the enzyme responsible for the synthesis of SAM from methionine.
During our study of other neurological diagnostic groups it became apparent that patients with Alzheimer's dementia had remarkably low levels of CSF SAM, significantly lower than in depression (table 1) . This suggests that disturbance in methylation in the brain may also be important in some forms of dementia. The administration of oral SAM to four of our patients was associated with an increase in CSF SAM to within the control range (table 3) and was accompanied by an improvement in mood and cognitive measures such as to justify further controlled trials of SAM in this clinical situation.2' The potential importance of such studies has recently been indicated by Holliday22 who has reviewed the role of DNA methylation in "epigenetic" mechanisms which influence the long term functioning of tissues. He summarises evidence to support the view that the gradual loss of methyl groups derived from SAM could contribute to ageing.
